Integrated Quantitative Investments LLC Makes New $271,000 Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Integrated Quantitative Investments LLC acquired a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 4,900 shares of the specialty pharmaceutical company’s stock, valued at approximately $271,000.

Other large investors have also recently made changes to their positions in the company. US Bancorp DE grew its position in ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after buying an additional 531 shares during the period. KBC Group NV boosted its stake in ANI Pharmaceuticals by 89.2% in the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after acquiring an additional 600 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at approximately $166,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after purchasing an additional 579 shares during the last quarter. Finally, HighTower Advisors LLC bought a new stake in shares of ANI Pharmaceuticals in the 3rd quarter worth approximately $222,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the sale, the vice president now owns 80,545 shares of the company’s stock, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the completion of the transaction, the senior vice president now owns 66,525 shares in the company, valued at $4,048,711.50. This represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,200 shares of company stock worth $191,776 in the last three months. Corporate insiders own 12.70% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on ANIP. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 target price for the company. StockNews.com raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, March 14th. HC Wainwright reaffirmed a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price for the company. Finally, Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a “buy” rating and a $80.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $79.75.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $67.52 on Friday. The company has a 50 day moving average of $61.45 and a 200 day moving average of $58.78. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The stock has a market cap of $1.47 billion, a P/E ratio of -122.76 and a beta of 0.63. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $70.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.